P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

Table 3 Inhibitory effect of VX-745 on hyperalgesia in the Hargraeves model

COMPOUND	PAW WITHDRAWAL TIME PRE-DRUG TREATMENT (Seconds)	PAW WITHDRAWAL TIME POST-DRUG TREATMENT (Seconds)
Vehicle	11.5 ± 0.8	7.4 ± 0.5
Indomethacin (10 mg/kg)	12.3 ± 0.9	16.3 ± 1.2*
VX-745 (30 mg/kg)	10.6 ± 0.4	14.9 ± 0.6*
VX-745 (10 mg/kg)	11.7 ± 0.8	12.1 ± 0.7*
VX-745 (3 mg/kg)	12.0 ± 0.7	9.4 ± 1.0*

The data are presented as the time for paw withdrawal from the heat source in seconds and are the mean ± S.E.M. from 10 rats per treatment group. The asterisk denotes a statistically significant difference (p < 0.05) between the vehicle and drug treatment groups.

ISSN: 1476-9255